Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Binder

Showing results (291-300 of 653) with videos related to

Pageof 66
Sort By:
Invasion & Metastasis|January 1, 1985
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumorsJ C Kirchheimer, H Pflüger, P Ritschl, et al.
Zeitschrift Fur Kardiologie|January 1, 1993
The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activatorK Huber, R Beckmann, F Rauscha, et al.
Thrombosis Research|July 15, 1996
The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parametersM Zehetgruber, R Beckmann, H Gabriel, et al.
Thrombosis Research|June 1, 1992
Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteinsE Petzelbauer, D Seiffert, R Beckmann, et al.
American Journal of Respiratory and Critical Care Medicine|October 1, 1994
Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertensionK Huber, R Beckmann, H Frank, et al.
Neuroimage|June 1, 2005
Some neurophysiological constraints on models of word namingJ R Binder, D A Medler, R Desai, et al.
The Journal of Biological Chemistry|May 15, 1989
Predicted structures of apolipoprotein II mRNA constrained by nuclease and dimethyl sulfate reactivity: stable secondary structures occur predominantly in local domains via intraexonic base pairingS P Hwang, M Eisenberg, R Binder, et al.
Thrombosis Research|June 15, 1992
Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancerK Okajima, I Kohno, J Tsuruta, et al.
The Journal of Biological Chemistry|January 28, 1994
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitorD Seiffert, G Ciambrone, N V Wagner, et al.
Blood|March 1, 1993
Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cellsG Christ, D Seiffert, P Hufnagl, et al.
Pageof 66

Showing results (291-300 of 653) with videos related to

Sort By:
Pageof 66
Invasion & Metastasis|January 1, 1985
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumorsJ C Kirchheimer, H Pflüger, P Ritschl, et al.
Zeitschrift Fur Kardiologie|January 1, 1993
The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activatorK Huber, R Beckmann, F Rauscha, et al.
Thrombosis Research|July 15, 1996
The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parametersM Zehetgruber, R Beckmann, H Gabriel, et al.
Thrombosis Research|June 1, 1992
Modulation of heparin cofactor II activity by glycosaminoglycans and adhesive glycoproteinsE Petzelbauer, D Seiffert, R Beckmann, et al.
American Journal of Respiratory and Critical Care Medicine|October 1, 1994
Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertensionK Huber, R Beckmann, H Frank, et al.
Neuroimage|June 1, 2005
Some neurophysiological constraints on models of word namingJ R Binder, D A Medler, R Desai, et al.
The Journal of Biological Chemistry|May 15, 1989
Predicted structures of apolipoprotein II mRNA constrained by nuclease and dimethyl sulfate reactivity: stable secondary structures occur predominantly in local domains via intraexonic base pairingS P Hwang, M Eisenberg, R Binder, et al.
Thrombosis Research|June 15, 1992
Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancerK Okajima, I Kohno, J Tsuruta, et al.
The Journal of Biological Chemistry|January 28, 1994
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitorD Seiffert, G Ciambrone, N V Wagner, et al.
Blood|March 1, 1993
Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cellsG Christ, D Seiffert, P Hufnagl, et al.
Pageof 66